An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
Information source: Pfizer
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Plaque Psoriasis Patients
Intervention: Enbrel treatment (Other)
Sponsored by: Pfizer
Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
With the new reimbursement criteria, we want:
To describe the average treatment duration of patients with Enbrel expressed as a number of
To describe the number of patients who receive continuous treatment To describe the number
of patients who receive intermittent treatment To describe the number of weeks off treatment
Official title: An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Number of Weeks of Etanercept Treatment
Number of Weeks of Off-Treatment
Psoriasis Area and Severity Index (PASI) Score
Percentage of Body Surface Area (BSA) Affected by Psoriasis
Number of Participants With Reasons for Treatmant Discontinuation
100 patients will be followed for at least 1 year
Minimum age: 18 Years.
Maximum age: N/A.
- Patient restarts or is starting treatment with Enbrel for his/her psoriasis in
alignment with reimbursement criteria
- Patients ≥18 year
- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
Locations and Contacts
Herestraat 49, Leuven 3000, Belgium
To obtain contact information for a study center near you, click here.
Starting date: September 2011
Last updated: May 28, 2014